📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Modified recombinant human IgG1-Fc is superior to natural intravenous immunoglobulin at inhibiting immune-mediated demyelination. (2021)

First Author: Baksmeier C

Attributed to: Tropical Infectious Disease Consortium: Expanding and Accelerating Product Development funded by UKRI

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/imm.13341

PubMed Identifier: 33880776

Publication URI: http://europepmc.org/abstract/MED/33880776

Type: Journal Article/Review

Volume: 164

Parent Publication: Immunology

Issue: 1

ISSN: 0019-2805